American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death
Open Access
- 31 January 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 125 (4), 577-583
- https://doi.org/10.1161/circulationaha.111.041160
Abstract
The availability of more sensitive biomarkers of myonecrosis and a new classification system from the universal definition of myocardial infarction (MI) have led to evolution of the classification of MI. The prognostic implications of MI defined in the current era have not been well described. We investigated the association between new or recurrent MI by subtype according to the European Society of Cardiology/American College of Cardiology/American Heart Association/World Health Federation Task Force for the Redefinition of MI Classification System and the risk of cardiovascular death among 13 608 patients with acute coronary syndrome in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). The adjusted risk of cardiovascular death was evaluated by landmark analysis starting at the time of the MI through 180 days after the event. Patients who experienced an MI during follow-up had a higher risk of cardiovascular death at 6 months than patients without an MI (6.5% versus 1.3%, P P P <0.001). After adjustment for important clinical covariates, the occurrence of any MI was associated with a 5-fold higher risk of death at 6 months (95% confidence interval 3.8–7.1), with similarly increased risk across subtypes. MI is associated with a significantly increased risk of cardiovascular death, with a consistent relationship across all types as defined by the universal classification system. These findings underscore the clinical relevance of these events and the importance of therapies aimed at preventing MI. URL: http://www.clinicaltrials.gov . Unique identifier: NCT00097591.Keywords
This publication has 22 references indexed in Scilit:
- Balancing Benefit and Bleeding Risk of Antithrombotic Agents in the Individual Patient With an Acute Coronary SyndromeCirculation, 2010
- Cangrelor — A Champion Lost in Translation?New England Journal of Medicine, 2009
- Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 SubstudyAmerican Heart Journal, 2009
- Implications of the universal definition of myocardial infarctionNature Clinical Practice Cardiovascular Medicine, 2008
- Universal Definition of Myocardial InfarctionCirculation, 2007
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Baseline troponin level: key to understanding the importance of post-PCI troponin elevationsEuropean Heart Journal, 2006
- Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortalityThe American Journal of Cardiology, 2004
- Troponin I elevation and cardiac events after percutaneous coronary interventionAmerican Heart Journal, 2003
- Frequency and long-term impact of myonecrosis after coronary stentingPublished by Oxford University Press (OUP) ,2002